Article
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.
JAMA cardiology - 1 Nov 2023
Vissing Christoffer Rasmus, Axelsson Raja Anna, Day Sharlene M, Russell Mark W, Zahka Kenneth, Lever Harry M, Pereira Alexandre C, Colan Steven D, Margossian Renee, Murphy Anne M, Canter Charles, Bach Richard G, Wheeler Matthew T, Rossano Joseph W, Owens Anjali T, Benson Lee, Mestroni Luisa, Taylor Matthew R G, Patel Amit R, Wilmot Ivan, Thrush Philip, Soslow Jonathan H, Becker Jason R, Seidman Christine E, Lakdawala Neal K, Cirino Allison L, McMurray John J V, MacRae Calum A, Solomon Scott D, Bundgaard Henning, Orav E John, Ho Carolyn Y
Abstract excerpt
Importance: Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression. Objective: To explore the potential for valsartan to modify disease development, and to characterize short-term...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.